Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qingyi Yang

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
ACS Medicinal Chemistry Letters|April 21, 2016
Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided DesignJason B Cross, Jing Zhang, Qingyi Yang, et al.
Antiviral Research|February 1, 2026
Analysis of Ibuzatrelvir's Activity Against SARS-CoV-2 Circulating Variants and In Vitro Resistance MutationsIrina Yurgelonis, Devendra K Rai, Zhenghui Li, et al.
Journal of Chemical Theory and Computation|December 29, 2023
Development and Comprehensive Benchmark of a High-Quality AMBER-Consistent Small Molecule Force Field with Broad Chemical Space Coverage for Molecular Modeling and Free Energy CalculationBai Xue, Qingyi Yang, Qiaochu Zhang, et al.
Science Advances|July 24, 2024
In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillanceYuao Zhu, Irina Yurgelonis, Stephen Noell, et al.
Nature Structural & Molecular Biology|December 15, 2022
Structural basis of the acyl-transfer mechanism of human GPAT1Zachary Lee Johnson, Mark Ammirati, David Jonathan Wasilko, et al.
Journal of Medicinal Chemistry|February 21, 2023
Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite LossMichelle R Garnsey, Aaron C Smith, Jana Polivkova, et al.
Science (New York, N.Y.)|November 2, 2021
An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, et al.
Journal of Medicinal Chemistry|April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
ACS Medicinal Chemistry Letters|April 21, 2016
Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided DesignJason B Cross, Jing Zhang, Qingyi Yang, et al.
Antiviral Research|February 1, 2026
Analysis of Ibuzatrelvir's Activity Against SARS-CoV-2 Circulating Variants and In Vitro Resistance MutationsIrina Yurgelonis, Devendra K Rai, Zhenghui Li, et al.
Journal of Chemical Theory and Computation|December 29, 2023
Development and Comprehensive Benchmark of a High-Quality AMBER-Consistent Small Molecule Force Field with Broad Chemical Space Coverage for Molecular Modeling and Free Energy CalculationBai Xue, Qingyi Yang, Qiaochu Zhang, et al.
Science Advances|July 24, 2024
In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillanceYuao Zhu, Irina Yurgelonis, Stephen Noell, et al.
Nature Structural & Molecular Biology|December 15, 2022
Structural basis of the acyl-transfer mechanism of human GPAT1Zachary Lee Johnson, Mark Ammirati, David Jonathan Wasilko, et al.
Journal of Medicinal Chemistry|February 21, 2023
Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite LossMichelle R Garnsey, Aaron C Smith, Jana Polivkova, et al.
Science (New York, N.Y.)|November 2, 2021
An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, et al.
Journal of Medicinal Chemistry|April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Pageof 5